Recent data suggest that Donanemab, an investigational therapeutic , has the potential to reduce the development of early-stage cognitive decline. This treatment focuses on reducing amyloid plaques https://bookmark-dofollow.com/story28149533/donanemab-an-promising-novel-dementia-approach